Since the PI3K-AKT-mTOR pathway is commonly activated in advanced stages of PCa, this pathway may represent a potential target to effectively inhibit PCa growth and to overcome resistance of AR targeted therapy [11,169]. Here, MTOR is linked to posterior cortical atrophy.